Drug intelligence / Profile preview

CKD-845

Development stage: Phase 1
Lead developer: Chong Kun Dang Pharmaceutical
Modality: Small Molecules
Administration: Intramuscular

Overview

CKD-845 is an intramuscularly injected testosterone formulation developed by Chong Kun Dang Pharmaceutical for the treatment of male hypogonadism. As a testosterone replacement therapy, it is designed to address testosterone deficiency in hypogonadal men by restoring physiological hormone levels. The drug acts as an agonist of the androgen receptor, which is critical for the development and maintenance of male sexual characteristics and overall metabolic health. CKD-845 is currently undergoing Phase 1 clinical evaluation to compare its pharmacokinetic profile and safety against a reference testosterone product, D309.

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on CKD-845.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CKD-845.

Explore the full profile